A Strategy for Countering Fraudulent Trademark Registrations at the Patent and Trademark Office
Summary
The Biden Administration should enhance the efforts of the U.S. Patent and Trademark Office (PTO) to defend against fraudulent trademark registrations. Since 2015, the PTO has struggled to cope with a rising flood of fraudulent trademark applications originating mainly from China. One study indicates that as many as two-thirds of Chinese trademark applications for certain classes of goods include falsified evidence that the applicant is using the mark in commerce in the United States — a requirement for trademark registration under U.S. law. High proportions (up to 40%) of these fraudulent applications survive the PTO’s application-review process and result in fraudulent trademark registrations.
Urgent action is necessary. The PTO reports that the trademark application rate has recently surged to extreme levels, which has doubled the number of applications awaiting examination. Many of these applications likely contain fraudulent claims of use. Identifying and denying fraudulent claims will help ensure that only those businesses that are actually using their trademarks in U.S. commerce benefit from the U.S. trademark system. In addition to creating a fair playing field for companies (both American and foreign) that abide by the rules, countering fraudulent trademark registrations will support American economic recovery from the COVID-19 pandemic by providing small businesses with robust protection for brand names of new products.
This is a bipartisan, commonsense measure to reauthorize the Technology Modernization Fund (TMF) before it expires in September 2026.
Many states are introducing AI policies and task forces, but lack the “AI-native” personnel to build and maintain initiatives. To address this in the short term, states should establish AI Resilience Cohorts to embed early-career technologists in key offices to support state AI initiatives. Right now, Virginia and New Jersey have the opportunity to take […]
We sat down with biomedical research pioneer Lee Hood to talk moonshots, metascience in medicine, and the Human Phenome Initiative.
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.